Growth-hormone and prolactin excess

Lancet

Volumn 352, Issue 9138, 1998, Pages 1455-1461

  Colao, Annamaria ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; LISURIDE; OCTREOTIDE; PERGOLIDE; POLYGLACTIN; PROLACTIN; QUINAGOLIDE; SOMATOSTATIN DERIVATIVE;

ABDOMINAL PAIN; ACROMEGALY; CARDIOMYOPATHY; DEPRESSION; DIARRHEA; DRUG FORMULATION; DRUG HALF LIFE; ENDOCRINE TUMOR; GALLSTONE; GROWTH HORMONE RELEASE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; NAUSEA; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; SLOW RELEASE FORMULATION; VERTIGO; VOMITING;

EID: 0032585243     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03356-X     Document Type: Review

References (70)

1. 1 Melmed S, Ho K, Klibanski A, Reichlin S, Thorner MO. Recent advances in pathogenesis, diagnosis and management of acromegaly. J Clin Endocrinol Metab 1995; 80: 3395-402.
2. 2 Colao A, Merola B, Ferone D, Lombardi G. Extensive personal experience: acromegaly. J Clin Endocrinol Metab 1997; 82: 2777-81.
3. 3 Aron DC, Tyrrell B, Wilson CB. Pituitary tumors: current concepts in diagnosis and management. World J Med 1995; 162: 340-52.
4. 4 Shimon I, Melmed S. Pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997; 82: 1675-81.
5. 5 Lamberts SWJ, van der Lely AJ, de Herder WW. Clinical and medical diagnosis of acromegaly. Metabolism 1995; 44 (suppl 1): 15-17.
6. 6 Delhougne B, Deneux C, Abs R, et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995; 80: 3223-26.
7. 7 Jenkins PJ, Fairclough PD, Richards T, et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol 1997; 47: 17-22.
8. 8 Colao A, Balzano A, Ferone D, et al. Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol 1997; 47: 23-28.
9. 9 Barkan A. Acromegalic arthropathy and sleep apnea. J Endocrinol 1997; 155: S41-44.
10. 10 Lombardi G, Colao A, Marzullo P, et al. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J Endocrinol 1997; 155: S33-36.
11. 11 de Herder WW, van der Lely AJ, Janssen JAMJL, et al. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. Clin Endocrinol 1995; 43: 501-15.
12. 12 Stoffel-Wagner B, Springel W, Bidlingmeier F, Klingmuller D. A comparison of different methods for diagnosing acromegaly. Clin Endocrinol 1997; 46: 531-37.
13. 13 Chapman IM, Hartan ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab 1994; 78: 1312-19.
14. 14 Bates A, vant'Hoff W, Jones J, Clayton R. An audit of outcome of treatment in acromegaly. QJM 1993; 86: 293-99.
15. 15 Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson AK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994; 41: 95-102.
16. 16 Clayton RN. New developments in the management of acromegaly: should we achieve absolute biochemical cure? J Endocrinol 1997; 155: S23-29.
17. 17 Fahlbush R, Honegger J, Buchfelder M. Acromegaly: the place of the neurosurgeon. Metabolism 1996; 45: 65-66.
18. 18 Yamada S, Aibat T, Takada K, et al. Retrospective analysis of long-term surgical results in acromegaly: preoperative and post-operative factors predicting outcome. Clin Endocrinol 1996; 45: 291-98.
19. 19 Sheaves R, Jenkins P, Blackburn P, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996; 45: 407-13.
20. 20 Fahlbush R, Giovannelli M, Buchfelder M, Losa M, and participants of the Conference on Medical and Surgical Treatment of Pituitary Adenomas. Zurich, Oct 5, 1991: consensus statement in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. J Endocrinol Invest 1993; 16: 449-60.
21. 21 Ezzat S, Horvath E, Harris AG, Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 1994; 79: 113-18.
22. 22 Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997; 82: 3308-14.
23. 23 Jho HD, Carrau RL, Ko Y. Endoscopic pituitary surgery. In: Wilkins RH, Rengachary SS, eds. Neurosurgical operative atlas. Park Ridge, Ill: Am Assoc Neurol Surg 1996; 5: 1-12.
24. 24 Wass JAH. Evidence for the effectiveness of radiotherapy in the treatment of acromegaly. J Endocrinol 1997; 155: S57-58.
25. 25 Eastman RC, Gorden P, Glatstein E, et al. Radiation therapy for acromegaly. Endocrinol Metab Clin North Am 1992; 21: 693-712.
26. 26 Brierle JD, Gosbodarowicz MK, Panzanellat J, Sutcliffe SB, Simpson WJ, Tsang RW. The role of radiation therapy in clinically hormonally active pituitary adenomas. Radiat Oncol 1996; 41: 55-53.
27. 27 Barkan A, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997; 82: 3187-91.
28. 28 Brada M, Ford D, Aschley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. BMJ 1992; 304: 1343-46.
29. 29 Jones A. Radiation oncogenesis in relation to the treatment of pituitary tumours. Clin Endocrinol 1991; 35: 379-97.
30. 30 Jaffe CA, Barkan AL. Acromegaly: recognition and treatment. Drugs 1994; 47: 425-45.
31. 31 Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997; 82: 518-23.
32. 32 Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 221-35.
33. 33 Abs R, Versholst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998; 83: 374-78.
34. 34 Chiodini PG. Attanasio R, Cozzi R, et al. CV 205-502 in acromegaly. Acta Endocrinol (Copenh) 1993; 128: 389-93.
35. 35 Hale R, Besser GM, Schally A, et al. Actions of growth hormone release inhibitory hormone in healthy men and in acromegaly. Lancet 1973; ii: 581-84.
36. 36 Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-54.
37. 37 Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998; 83: 775-79.
38. 38 Colao A, Marzullo P, Vallone G, et al. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 1998; 83: 2121-25.
39. 39 Redfern JS, Fortuner WJ II. Octreotide-associated biliary tract dysfunction and gallstones formation: pathophysiology and management. Am J Gastroenterol. 1995; 90: 1042-52.
40. 40 Giusti M, Gussoni G, Cuttica CM, Giordano G, and the Italian Multicenter Slow Release Lanreotide Study Group. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly; six month report on an Italian multicenter study. J Clin Endocrinol Metab 1996; 81: 2089-97.
41. 41 Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997; 82: 18-22.
42. 42 Lancranjan I, Bruns C, Grass P, et al. Sandostatin-LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996; 45: 67-71.
43. 43 Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR): a review of its phamacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53: 681-99.
44. 44 Costello RT. Subclinical adenoma of the pituitary gland. Am J Pathol 1936; 12: 205-16.
45. 45 Burrow GN, Wortzman G, Rewcastle NB, et al. Microadenomas of the pituitary gland and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1980; 304: 156-58.
46. 46 Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989; 68: 412-18.
47. 47 Molitch ME, Thorner MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997; 82: 996-1000.
48. 48 Molitch ME. Prolactinoma. In: Melmed S, ed. The pituitary. Boston: Blackwell Scientific, 1995: 443-77.
49. 49 Ciccarelli E, Ghigo E, Miola C, Gandini G, Muller EE, Camanni F. Long-term follow-up of cured prolactinoma patients after successful adenomectomy. Clin Endocrinol 1990; 32: 583-92.
50. 50 Webster J, Page MD, Bevan JS, Richards SH, Douglas-Jones AG, Scanlon MF. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function test. Clin Endocrinol 1992; 36: 35-44.
51. 51 Grossman A, Cohen BC, Charlesworth M, et al. Treatment of prolactinomas with megavoltage radiotherapy. BMJ 1984; 228: 1105-09.
52. 52 Sheline GE, Grossman A, Jones AE, et al. Radiation therapy for prolactinomas. In: Black PMcL, Zervas NT, Ridgway EC, et al, eds. Secretory tumors of the pituitary gland: progress in endocrine research and therapy. New York: Raven Press, 1984: 93-108.
53. 53 Cunnah D, Besser GM. Management of prolactinomas. Clin Endocrinol 1991; 34: 231-35.
54. 54 Turner TH, Cookson JC, Wass JAH, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonist. BMJ 1984; 289: 1101-03.
55. 55 Brue T, Pellegrini I, Gunz G, et al. Effects of dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992; 74: 577-84.
56. 56 Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82: 876-83.
57. 57 Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-09.
58. 58 Biller BMK, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 2338-43.
59. 59 Ferrari C, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 1997; 46: 409-13.
60. 60 Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997; 82: 3574-79.
61. 61 Schettini G, Lombardi G, Merola B, et al. Rapid and long-lasting suppression on prolactin secretion and shrinkage of prolactinomas with improved tolerability after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). Clin Endocrinol 1990; 33: 161-69.
62. 62 Jenkins PJ, Jain A, Jones SL, Besser GM, Grossman AB. Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy. Clin Endocrinol (Oxf) 1996; 45: 447-51.
63. 63 Kletzky OA, Wermesch M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil Steril 1989; 51: 269-72.
64. 64 Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993; 59: 671-73.
65. 65 Colao A, De Rosa M, Sarnacchiaro F, et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Em J Endocrinol 1996; 135: 548-52.
66. 66 De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998; 138: 286-93.
67. 67 Klibanski A, Neer RM, Beitins IZ, Ridgway C, Zarvas NT, McArthur JW. Decreased bone density in amenorrheic women. N Engl J Med 1980; 303: 1511-14.
68. 68 Greenspan SL, Oppenheim DS, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989; 110: 526-31.
69. 69 Di Somma C, Colao A, Di Sarno A, et al. Bone markers and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998; 83: 807-13.
70. 70 Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Lancet 1984; ii: 187-92.